[The anticancer effect of artesunate and its mechanism]. 2002

Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
Unit of Chinese Traditional and Herbal Drugs, First Affiliated Hospital, Guangxi Traditional Chinese Medical University, Nanning 530001, China. wq@gxtcmu.edu.cn

OBJECTIVE To study the anticancer effect of artesunate and its mechanism. METHODS To observe the effect of artesunate on the growth of solid tumor and the expression of PCNA, Bcl-2 and Bax genes in mice bearing H22 solid hepatic carcinoma. RESULTS After administration of artesunate (ig, 300 mg.kg-1.d-1 x 7 d), growth of solid tumor was obviously inhibited, the tumor inhibitory rates were 49.1%, 48.7% and 46.6% and 46.6% in 3 experiments. The apoptosis of liver cancer cells were increased. Immunohistochemical staining showed that the number of Bcl-2 protein positive cells were decreased, but the number of Bax protein positive cells were increased. The PCNA positive cells were significantly lower than those in the control group. CONCLUSIONS Artesunate showed obvious anticancer activity on H22 hepatic carcinoma bearing mice and undergo apoptosis of liver cancer cells. The mechanism of anticancer effect of artesunate may be related to down-regulation of the expression of PCNA and Bcl-2 genes and up-regulation of the expression of Bax gene.

UI MeSH Term Description Entries
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008297 Male Males
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000077332 Artesunate A water-soluble, semi-synthetic derivative of the sesquiterpene lactone artemisinin with anti-malarial, anti-schistosomiasis, antiviral, and potential anti-neoplastic activities Dihydroartemisinine-12-alpha-succinate,Malacef,Malartin,SM 804,SM-804,Sodium Artesunate,Succinyl Dihydroartemisinin,Dihydroartemisinin, Succinyl,Dihydroartemisinine 12 alpha succinate,SM804
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
July 2012, Yao xue xue bao = Acta pharmaceutica Sinica,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
January 1999, Journal of Asian natural products research,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
January 2015, Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
January 2020, Anti-cancer agents in medicinal chemistry,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
January 2018, Anti-cancer agents in medicinal chemistry,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
August 2023, Chinese journal of integrative medicine,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
October 2005, Acta pharmacologica Sinica,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
November 2021, Oncology letters,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
January 2015, The Enzymes,
Qin Wang, and Li-mao Wu, and Yi Zhao, and Xi-liu Zhang, and Nai-ping Wang
October 2002, Journal of alternative and complementary medicine (New York, N.Y.),
Copied contents to your clipboard!